impress growth ep upsid underscor
strength fundament cadenc new
product drive continu growth
signific earn upsid org growth reinforc jnj sustain
underli growth profil market react favor jnj result despit
on-going potenti litig risk face compani strong growth pharma
roughli in-lin intra-quart analysi publish sept boost
better-than-expect growth devic show sequenti improv
litig overhang remain key challeng near-term stock
perform result recent cadenc new product pipelin execut
reinforc strength breadth jnj underli growth driver investor gain
greater clariti regard rang potenti liabil face compani expect stock
perform improv driven increasingli jnj solid fundament demonstr
reiter outperform rate rais target
upsid driven pharma vs cse devic vs
cse immunolog oncolog neurosci key
driver pharma growth also benefit less sever gener pressur
zytiga vs estim devic growth led
intervent solut join quarter vision ortho
vs
guidanc increas new organ sale growth guidanc
equat bil bil management also
rais ep guidanc y/i
valuat target price base ebitda multipl
unchang ebitda bil previous bil risk unexpect
challeng pharma product pipelin setback macro challeng around drug price
unexpect advers impact litig regulatori qualiti issu
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek
busi compani cover research report result investor awar firm may conflict
interest could affect object report investor consid report singl factor make
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
johnson johnson hold compani engag
 manufactur sale rang product health care field
oper compani organ busi segment
one-year valuat scenario base
ev/ebitda ebitda bil
scenario base high-growth segment grow
growth grow
one-year valuat grey scenario base
ev/ebitda grey ebitda bil
grey scenario base high-growth segment grow
growth grow
 close
pharmaceut bil mil y/i
cc oper vs cse cc
immunolog sale driven strong uptak stelara crohn diseas
tremfya
discounts/reb biosimilar competit
psoriasi partial off-set remicad due
oncolog sale driven darzalex market growth share gain
 eu imbruvica off-set lower zytiga sale lower velcad sale
neurosci sale driven strength invega sustenna partial
off-set cannib risperd consta
medic devic bil mil y/i
intervent solut sale oper driven continu dd afib
orthopaed oper driven hip sale trauma
knee spine
surgeri sale strength advanc surgeri gener
surgeri partial off-set specialti surgeri
vision sale oper driven contact lenses/oth
consum bil mil y/i
beauti sale driven dr ci labo acquisit along share
gain neutrogena aveeno partial off-set roc divestitur
over-the-counter sale driven zarbe acquisit along share
market growth primarili tylenol zyrtec
babi sale driven primarili last year comp relat
johnson relaunch along competit pressur aspac declin
wipe latam
addit detail takeaway
pharmaceut bil mil y/i
cc oper vs cse cc
immunolog sale bil mil oper growth
quarter driven strong uptak stelara crohn diseas strong uptak
tremfya psoriasi expand indic simponi aria well overal
immunolog market growth remicad sale declin due increas discounts/reb
infecti diseas sale mil mil oper strong
sale symtuza launch juluca hiv partial off-set increas
competit prezista/prezcobix/rezolsta prezista ou loe loss exclus
neurosci sale bil mil oper paliperidon
sustenna/xeplion result new patient start partial off-set cannib risperd
invega trinza/trevicta
strength
oncolog sale bil mil oper darzalex
continu strong market growth share gain eu driven patient uptak
line therapi sale growth includ one-tim adjust relat reimburs
discuss ou countri posit impact ww oper growth
mil imbruvica growth driven increas ww patient uptak higher
market share growth across multipl indic primarili cll lower sale zytiga
 result gener competit partial off-set strong sale share
growth eu erleada growth driven launch uptak along share gain non-
metastat castration-resist prostat cancer avail eight emea countri
erleada grew gain share quarter final velcad sale
result gener competit
pulmonari hypertens sale mil mil
oper growth quarter driven strong sale opsumit uptravi
result continu market growth share gain sale tracleer lower due
gener competit cannib opsumit
cardiovascular/metabolism/oth sale bil mil
oper sale xarelto flat volum growth off-set higher cost
patient access higher donut hole util legisl rebat chang
invokana/invokamet sale lower due share loss competit pressur
safeti label updat
salesy/i chg cc cg org cg salesy/i chg cc cg org metabolism/ charl martineau pm univers toronto octob
medic devic bil mil y/i
intervent solut sale mil mil oper
electrophysiolog grew driven continu dd afib procedur growth along strong
thermocool smarttouch sf contact sens cathet diagnost cathet sale
orthopaed sale bil mil oper hip sale
mil mil oper growth driven jnj
leadership posit anterior approach strong market demand acti stem
adopt kincis surgic autom system knee sale mil mil
oper manag cite above-market dd ou growth
new product like attun revis partial off-set competit pressur trauma
sale mil mil oper driven strong market
growth continu uptak new product spine sale mil mil
oper base busi declin spine partial
off-set growth sport led monovisc growth new product dd
growth aspac ortho price pressur show modest improv compar
 pure price still neg across categori spine hip trauma pure price
declin knee
surgeri sale bil mil oper advanc
surgeri sale driven endocutt led aspac market
growth uptak new product partial off-set share loss robot well
tougher comp last year biosurgeri driven growth region
led aspac led ou growth mainli aspac due market
growth share gain new product along growth emea gener surgeri growth
led wound closur growth driven strong perform aspac due
market share growth china well market growth share gain
convent barb sutur specialti surgeri growth led asp divestitur
partial off-set mentor growth
vision sale bil mil oper contact
lenses/oth sale mil mil oper
growth led daili dispos oasi famili well forward buy ahead
consumpt tax chang japan surgic sale mil mil
oper led strength ou cataract result market perform
iol dd aspac growth partial off-set competit pressur
salesy/i chg cc cg org cg salesy/i chg cc cg org cg medic charl martineau pm univers toronto octob
consum bil mil y/i
babi sale mil mil oper declin
quarter driven primarili last year comp relat johnson relaunch
along competit pressur aspac declin wipe latam
beauti sale bil mil oper growth driven
dr ci labo acquisit along share gain neutrogena aveeno partial off-set
roc divestitur
oral sale mil mil oper growth
driven strength listerin nightli reset emea off-set soft floss/tap
over-the-counter sale bil mil oper growth driven
zarbe acquisit share market growth tylenol zyrtec zyrtec share
gain off-set retail stock dynam
women sale mil mil oper
declin quarter result declin liner market venezuela
wound care/oth sale mil mil oper due
strength band-aid neosporin partial off-set compe divestitur
salesy/i chg cc cg org cg salesy/i chg cc cg org estimate varianc charl martineau pm univers toronto octob
 oper margin bp
sale net cog lower share partial off-set higher
tax non-op incom net interest deliv ep upsid rel
estim consensu higher cog result fx pharma higher
expect tax rate due adjust tax reserv posit recal
record favor financi impact approxim relat tax reform
includ estim tax benefit transit provis swiss tax reform partial
off-set adjust exist tax reserv posit neg impact effect tax
manag rais organ sale growth guidanc
report bil ep guidanc also increas
estimate bpop bpnon-op bpnet chg y/i charl martineau pm univers toronto octob
chang model
increas sale estim increas ep estim
reflect new guidanc also made rel minor adjust top-lin
project beyond increas sale estim per year averag
increas year ep estim
figur chang model
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
